Search
Zomepirac
go.drugbank.com/drugs/DB04828ApprovedWithdrawnZomepirac, formerly marketed as Zomax tablets, was associated with fatal and near-fatal anaphylactoid reactions. The manufacturer voluntarily removed Zomax tablets from the Canadian, US, and UK markets in March 1983.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesZimelidine
go.drugbank.com/drugs/DB04832ApprovedWithdrawnZimelidine has been banned worldwide due to serious, sometimes fatal, cases of central and/or peripheral neuropathy known as Guillain-Barré syndrome and due to a peculiar hypersensitivity reaction involving many organs including skin exa...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 CYP3A InhibitorsCyclandelate
go.drugbank.com/drugs/DB04838ApprovedWithdrawnA direct-acting smooth muscle relaxant used to dilate blood vessels. It may cause gastrointestinal distress and tachycardia. Cyclandelate is not approved for use in the U.S. or Canada, but is approved in various European countries.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesDebrisoquine
go.drugbank.com/drugs/DB04840ApprovedIt is also noteworthy in being a substrate for a polymorphic cytochrome P-450 enzyme.
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesRoxadustat
go.drugbank.com/drugs/DB04847ApprovedInvestigationalRoxadustat is a first-in-class hypoxia-inducible factor prolyl hydroxylase inhibitor used to treat anemia associated with chronic kidney disease. It works by reducing the breakdown of the hypoxia-inducible factor (HIF), which is a transc...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 SubstratesElacridar
go.drugbank.com/drugs/DB04881InvestigationalElacridar (GW120918) is an oral bioenhancer that targets multiple drug resistance in tumors. In many cases, the appearance of multidrug resistance in cancer is due to a change in expression of protein inhibitors. As of August 2007 elacri...
Categories: P-glycoprotein inhibitorsDapoxetine
go.drugbank.com/drugs/DB04884InvestigationalDapoxetine is a selective serotonin reuptake inhibitor, for the treatment of premature ejaculation. In a phase II proof-of-concept study conducted by PPD, dapoxetine demonstrated a statistically significant increase in ejaculatory latenc...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InhibitorsVapreotide
go.drugbank.com/drugs/DB04894InvestigationalVapreotide is a synthetic octapeptide somatostatin analog. It was being studied for the treatment of cancer.
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 InhibitorsXimelagatran
go.drugbank.com/drugs/DB04898ApprovedWithdrawnXimelagatran is an anticoagulant intended to become a replacement for warfarin by overcoming the dietary restrictions, drug interaction, and monitoring issues associated with the former. In 2006, its manufacturer AstraZeneca announced th...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 SubstratesOspemifene
go.drugbank.com/drugs/DB04938ApprovedOspemifene is a new selective non-hormonal estrogen receptor modulator (SERM) that is used for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause. FDA approved on February 26, 2013.
Synonyms: 2-(p-((Z)-4-Chloro-1,2-diphenyl-1-butenyl)phenoxy)ethanolCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 Substrates